Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin

被引:4
作者
Bukowska-Osko, Iwona [1 ]
Pawelczyk, Agnieszka [1 ]
Perlejewski, Karol [1 ]
Kubisa, Natalia [1 ]
Cortes, Kamila Caraballo [1 ]
Rosinska, Magdalena [2 ]
Ploski, Rafal [3 ]
Fic, Maria [1 ]
Kazmierczak, Justyna [1 ]
Popiel, Marta [1 ]
Zabek, Piotr [4 ]
Horban, Andrzej [4 ]
Radkowski, Marek [1 ]
Laskus, Tomasz [1 ]
机构
[1] Med Univ Warsaw, Dept Immunopathol, Warsaw, Poland
[2] Natl Inst Hyg, Dept Epidemiol, PL-00791 Warsaw, Poland
[3] Med Univ Warsaw, Dept Med Genet, Warsaw, Poland
[4] Hosp Infect Dis, Warsaw, Poland
关键词
CHRONICALLY INFECTED PATIENTS; QUASI-SPECIES HETEROGENEITY; VIRAL BREAKTHROUGH; HIV; EVOLUTION; THERAPY; MORTALITY; PERSISTENCE; MUTATIONS; DEATH;
D O I
10.1371/journal.pone.0125604
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Association between hepatitis C virus (HCV) quasispecies and treatment outcome among patients with chronic hepatitis C has been the subject of many studies. However, these studies focused mainly on viral variable regions (E1 and E2) and usually did not include human immunodeficiency virus (HIV)-positive patients. The aim of the present study was to analyze heterogeneity of the 5'untranslated region (5'UTR) in HCV/HIV coinfected patients treated with interferon and ribavirin. The HCV 5'UTR was amplified from serum and peripheral blood mononuclear cells (PBMC) samples in 37 HCV/HIV coinfected patients treated for chronic hepatitis C. Samples were collected right before treatment, and at 2, 4, 6, 8, 12, 20, 24, 36, 44, 48, 60, and 72 weeks. Heterogeneity of the 5'UTR was analyzed by single strand conformational polymorphism (SSCP), cloning and sequencing. Sustained virological response (SVR) was achieved in 46% of analyzed HCV/HIV co-infected patients. Stable SSCP band pattern was observed in 22 patients (62.9%) and SVR rate among these patients was 23%. Decline in the number of bands and/or shift in band positions were found in 6 patients (17.1%), 5 (83%) of whom achieved SVR (p=0.009). A novel viral genotype was identified in all but one of these patients. In 5 of these 6 patients a new genotype was dominant. 5'UTR heterogeneity may correlate with interferon and ribavirin treatment outcome. In the analyzed group of HCV/HIV coinfected patients, viral quasispecies stability during treatment favored viral persistence, whereas decrease in the number of variants and/or emergence of new variants was associated with SVR. Among injection drug users (IDU) patients, a new genotype may become dominant during treatment, probably due to the presence of mixed infections with various strains, which have different susceptibility to treatment.
引用
收藏
页数:12
相关论文
共 41 条
[1]   Hepatitis C/HIV co-infection is associated with higher mortality in hospitalized patients with Hepatitis C or HIV [J].
Ananthakrishnan, A. N. ;
McGinley, E. L. ;
Fangman, J. ;
Saeian, K. .
JOURNAL OF VIRAL HEPATITIS, 2010, 17 (10) :720-729
[2]   The error threshold [J].
Biebricher, CK ;
Eigen, M .
VIRUS RESEARCH, 2005, 107 (02) :117-127
[3]   Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment [J].
Bolcic, F. ;
Sede, M. ;
Moretti, F. ;
Westergaard, G. ;
Vazquez, M. ;
Laufer, N. ;
Quarleri, J. .
ARCHIVES OF VIROLOGY, 2012, 157 (04) :703-711
[4]   Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients [J].
Booth, JCL ;
Kumar, U ;
Webster, D ;
Monjardino, J ;
Thomas, HC .
HEPATOLOGY, 1998, 27 (01) :223-227
[5]   Hepatitis C virus 5′ untranslated region variability correlates with treatment outcome [J].
Bukowska-Osko, I. ;
Radkowski, M. ;
Pawelczyk, A. ;
Rosinska, M. ;
Cortes, K. Caraballo ;
Ploski, R. ;
Berak, H. ;
Horban, A. ;
Stanczak, J. ;
Fic, M. ;
Laskus, T. .
JOURNAL OF VIRAL HEPATITIS, 2014, 21 (08) :551-559
[6]   Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection [J].
Chambers, TJ ;
Fan, XF ;
Droll, DA ;
Hembrador, E ;
Slater, T ;
Nickells, MW ;
Dustin, LB ;
DiBisceglie, AM .
JOURNAL OF VIROLOGY, 2005, 79 (05) :3071-3083
[7]  
Domingo E, 2006, CURR TOP MICROBIOL, V299, P51
[8]   Positional effect of mutations in 5'UTR of hepatitis C virus 4a on patients' response to therapy [J].
El Awady, Mostafa K. ;
Azzazy, Hassan M. ;
Fahmy, Ahmed M. ;
Shawky, Sherif M. ;
Badreldin, Noha G. ;
Yossef, Samar S. ;
Omran, Moataza H. ;
Zekri, Abdel Rahman N. ;
Goueli, Said A. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (12) :1480-1486
[9]   The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies [J].
Farci, P ;
Shimoda, A ;
Coiana, A ;
Diaz, G ;
Peddis, G ;
Melpolder, JC ;
Strazzera, A ;
Chien, DY ;
Munoz, SJ ;
Balestrieri, A ;
Purcell, RH ;
Alter, HJ .
SCIENCE, 2000, 288 (5464) :339-344
[10]   Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome [J].
Farci, P ;
Strazzera, R ;
Alter, HJ ;
Farci, S ;
Degioannis, D ;
Coiana, A ;
Peddis, G ;
Usai, F ;
Serra, G ;
Chessa, L ;
Diaz, G ;
Balestrieri, A ;
Purcell, RH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) :3081-3086